TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07089121: Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune Disorders

Sponsor: Cartesian Therapeutics · Phase: PHASE1/PHASE2 · Area: IMMUNOLOGY · Target Enrollment: 50 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$3,665,625

Rescue Site Savings

+$2,404,650

Unlock Full NCT07089121 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07089121 Rescue Dossier →